News | May 12, 2022
Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
The campaign aims to promote women’s health and wellness and urge them to visit the hospital for key medical check-ups
Docosanol Cream, 10% (OTC) has an estimated market size of US$60 million for twelve months ending December 2021 according to IQVIA
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
Subscribe To Our Newsletter & Stay Updated
